Donepezil and memantine can be used in combination and are commonly used to treat Alzheimer’s disease. Donepezil is primarily indicated for the treatment of patients with mild or moderate Alzheimer’s disease. It improves cognitive function in patients with Alzheimer’s disease by inhibiting acetylcholinesterase activity, which slows down the breakdown of acetylcholine in the synaptic gap. Memantine is mainly used for the treatment of moderate to severe Alzheimer’s disease. It can block neuronal damage caused by pathologically elevated glutamate concentration, and is also the current first-line drug for the treatment of severe Alzheimer’s disease. Donepezil and memantine improve the symptoms of Alzheimer’s disease patients through different pharmacological effects, and can be clinically used in combination. However, the specific patient, whether the need to combine the use of treatment, you need to follow the doctor’s instructions, to avoid blindly combined use of the two drugs.